UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14D-9

(Rule 14d-101)

SOLICITATION/RECOMMENDATION STATEMENT

UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

G1 THERAPEUTICS, INC.

(Name of Subject Company)

G1 THERAPEUTICS, INC.

(Name of Persons Filing Statement)

COMMON STOCK PAR VALUE $0.0001 PER SHARE

(Title of Class of Securities)

3621LQ109

(CUSIP Number of Class of Securities)

Monica Roberts Thomas, Esq.

Chief Legal and People Officer

700 Park Offices Drive, Suite 200

Research Triangle Park, NC 27709

With copies to:

Matthew J. Gardella, Esq. Jason S. McCaffrey, Esq. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. One Financial Center Boston, MA 02111 (617) 542-6000 Sarah Young, Esq. Ropes and Gray LLP Prudential Tower 800 Boylston Street Boston, MA 02199 (617) 951-7000

(Name, address, and telephone numbers of person authorized to receive notices and communications on behalf of the persons filing statement)

☒ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

The information set forth under Items 1.01, 5.02 and 9.01 of the Current Report on Form 8-K filed by G1 Therapeutics, Inc. on August 7, 2024 (including all exhibits attached hereto) is incorporated herein by reference.